loe-SAR-tan 
Absorption: Well absorbed but undergoes extensive first-pass hepatic metabolism, resulting in 33% bioavailability.
Distribution: Crosses the placenta.
Protein Binding: 99%.
Metabolism/Excretion: Undergoes extensive first-pass hepatic metabolism; 14% is converted to an active metabolite. 4% excreted unchanged in urine; 6% excreted in urine as active metabolite; some biliary elimination also occurs.
Half-life: 2 hr (6–9 hr for metabolite).
Contraindicated in:
Use Cautiously in:
CNS: dizziness, fatigue, headache, insomnia, weakness.
CV: chest pain, edema, hypotension.
EENT: nasal congestion.
Endo: hypoglycemia, weight gain.
GI: diarrhea, abdominal pain, dyspepsia, nausea.
GU: impaired renal function.
F and E: hyperkalemia.
MS: back pain, myalgia.
Misc: ANGIOEDEMA, fever.
Drug-Drug:
Hepatic Impairment
6 yr): Hypertension–0.7 mg/kg once daily (up to 50 mg/day), may be titrated up to 1.4 mg/kg/day (or 100 mg/day).Renal Impairment
6 yr): CCr <30 mL/min — Contraindicated.Therapeutic Classification: antihypertensives
Pharmacologic Classification: angiotensin II receptor antagonists
(Generic available)
NDC Code*